Literature DB >> 17904524

Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells.

Hiroyuki Fuke1, Katsuya Shiraki, Kazushi Sugimoto, Junichiro Tanaka, Tetsuya Beppu, Kentaro Yoneda, Norihiko Yamamoto, Keiichi Ito, Masahiro Masuya, Yoshiyuki Takei.   

Abstract

Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in various cancers and plays a crucial role in oncogensis, including the activation of genes encoding apoptosis inhibitors and cell-cycle regulators. We investigated the biological significance of the Janus kinase (Jak)-STAT pathway in human hepatocellular carcinoma (HCC). Constitutive activation of STAT3 was seen in 49.4% of human HCC specimens and in HCC cell lines. Jak inhibitor AG490 inhibited activation of STAT3 and markedly reduced cell viability without significant apoptosis. AG490 also induced S phase cell-cycle arrest with down-regulation of cyclin D1, A, E and up-regulation of p21, p27, phospho-Chk2. AG490 also inhibited caspase inhibitory proteins, such as XIAP and survivin, and augmented TRAIL-induced apoptosis. Our study suggests that the Jak-STAT pathway plays an important role in cell-cycle progression and resistance to apoptosis. Inhibition of the Jak-STAT pathway may thus be a therapeutic target for HCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904524     DOI: 10.1016/j.bbrc.2007.09.049

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

1.  A novel curcumin analogue is a potent chemotherapy candidate for human hepatocellular carcinoma.

Authors:  Ji-An Zhao; Mei-Xiang Sang; Cui-Zhi Geng; Shi-Jie Wang; Bao-En Shan
Journal:  Oncol Lett       Date:  2016-09-13       Impact factor: 2.967

2.  Downregulated Expression of PTPN9 Contributes to Human Hepatocellular Carcinoma Growth and Progression.

Authors:  Baoying Hu; Xia Yan; Fang Liu; Changlai Zhu; Huiling Zhou; Yuyan Chen; Jinxia Liu; Xingxing Gu; Runzhou Ni; Tianyi Zhang
Journal:  Pathol Oncol Res       Date:  2015-12-29       Impact factor: 3.201

3.  Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways.

Authors:  Ayumi Takakura; Erik A Nelson; Nadeem Haque; Benjamin D Humphreys; Kambiz Zandi-Nejad; David A Frank; Jing Zhou
Journal:  Hum Mol Genet       Date:  2011-08-05       Impact factor: 6.150

4.  Pro-apoptotic and anti-proliferative effects of mitofusin-2 via Bax signaling in hepatocellular carcinoma cells.

Authors:  Weilin Wang; Jianju Lu; Feng Zhu; Jianfeng Wei; Changku Jia; Yuanbiao Zhang; Lin Zhou; Haiyang Xie; Shusen Zheng
Journal:  Med Oncol       Date:  2010-12-29       Impact factor: 3.064

5.  Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours.

Authors:  B Nitzsche; C Gloesenkamp; M Schrader; M Ocker; R Preissner; M Lein; A Zakrzewicz; B Hoffmann; M Höpfner
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

6.  Suppressor of cytokine signaling 1 blocks mitosis in human melanoma cells.

Authors:  Verónica Parrillas; Laura Martínez-Muñoz; Borja L Holgado; Amit Kumar; Graciela Cascio; Pilar Lucas; José Miguel Rodríguez-Frade; Marcos Malumbres; Ana C Carrera; Karel Hm van Wely; Mario Mellado
Journal:  Cell Mol Life Sci       Date:  2012-09-23       Impact factor: 9.261

Review 7.  Hepatocellular carcinoma: targeting of oncogenic signaling networks in TRAIL resistant cancer cells.

Authors:  Sundas Fayyaz; Ilhan Yaylim; Saime Turan; Sobia Kanwal; Ammad Ahmad Farooqi
Journal:  Mol Biol Rep       Date:  2014-07-19       Impact factor: 2.316

8.  TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis.

Authors:  Naoki Ashimori; Benjamin D Zeitlin; Zhaocheng Zhang; Kristy Warner; Ilan M Turkienicz; Aaron C Spalding; Theodoros N Teknos; Shaomeng Wang; Jacques E Nör
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

9.  Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B.

Authors:  Guo-Hua Qiu; Xiaojin Xie; Fang Xu; Xiaohao Shi; Yue Wang; Linhong Deng
Journal:  Cytotechnology       Date:  2014-07-08       Impact factor: 2.058

10.  Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells.

Authors:  Haiyu Li; Zhenggang Ren; Xiaonan Kang; Lan Zhang; Xuefei Li; Yan Wang; Tongchun Xue; Yuefang Shen; Yinkun Liu
Journal:  BMC Cancer       Date:  2009-10-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.